[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649564":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":22,"locations":11,"responsibleParty":27,"collaborators":11,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":11,"eligibilityCriteria":35,"healthyVolunteers":36,"sex":37,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":11,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":11},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Comprehensive Lifestyle Intervention","EXPERIMENTAL",null,[13],"Other: Comprehensive Lifestyle Intervention",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":11},"Participants will receive a 24-week comprehensive lifestyle intervention：\n\n1. Individualized calorie-restricted low-carbohydrate diet: 800-1000 kcal\u002Fday if body weight \\\u003C80 kg, or 1000-1200 kcal\u002Fday if ≥80 kg; each meal includes \\~200 g vegetables and \\~100 g lean protein, with low fat\u002Fsugar\u002Fsalt; avoid high-fat meats and organ foods; daily food weighing and recording required.\n2. Aerobic exercise ≥150 min\u002Fweek at moderate intensity (50-70% of maximal heart rate) plus 2-3 resistance training sessions weekly.\n3. Monthly nutrition clinic visits for dietary adjustment.\n4. Self-monitoring of weight and fasting glucose ≥2 times\u002Fweek; monthly in-person follow-ups for the first 6 months.\n5. Hypoglycemic agents: baseline doses maintained; if fasting glucose \\\u003C7 mmol\u002FL and 2-h postprandial glucose \\\u003C10 mmol\u002FL, reduce 1-2 drug types per step; hypoglycemia episodes managed by investigator for dose reduction or discontinuation.",[9],[19],{"name":20,"affiliation":5,"role":21},"Pengfei Shan","PRINCIPAL_INVESTIGATOR",[23],{"name":20,"role":24,"phone":25,"phoneExt":11,"email":26},"CONTACT","86-0571-87783777","pengfeishan@zju.edu.cn",{"type":28,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100649564","the-impact-of-diabetes-remission-on-aging-100649564",false,"NCT07736040","The Impact of Diabetes Remission on Aging","The Ameliorative Role of Diabetes Remission in Aging: A Real-World-Based Prospective Clinical Cohort Study","Inclusion Criteria:\n\n1. Age 35 to 70 years.\n2. Diagnosis of type 2 diabetes mellitus according to WHO criteria, with disease duration ≤6 years.\n3. HbA1c between 7.0% and 9.5%, OR currently on glucose-lowering medications.\n4. Fasting C-peptide ≥1.0 ng\u002FmL.\n5. Fasting plasma glucose \\\u003C13.3 mmol\u002FL.\n6. BMI between 25 and 45 kg\u002Fm².\n7. Willing and able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. Diabetes mellitus secondary to other causes (e.g., Cushing's syndrome, hypothyroidism, glucagonoma, drug-induced, or genetic factors).\n2. BMI \\\u003C25 kg\u002Fm² or \\>45 kg\u002Fm²; weight loss \\>5% within the last 3 months; actively trying to lose weight within the last 3 months; use of weight-loss agents, contraceptives, glucocorticoids, or any medication other than antidiabetic drugs that may affect study outcome measurements within the last 3 months; history of bariatric surgery.\n3. Type 1 diabetes; type 2 diabetes duration \\>10 years; gestational diabetes; other specific types of diabetes.\n4. Diagnosis of acute metabolic diabetic complications (e.g., diabetic ketoacidosis or hyperosmolar hyperglycemic state) or diabetes insipidus within 30 days, or history thereof.\n5. Blood pressure ≥180\u002F110 mmHg or malignant hypertension.\n6. History of severe gastrointestinal disease; significant cardiac, hepatic, renal, or other systemic organ dysfunction (NYHA functional class ≥II; ALT and\u002For AST \\>4× upper limit of normal; GFR \\\u003C60 mL\u002Fmin); anemia or other hematological disorders; history of malignancy.\n7. History of bariatric surgery or other gastrointestinal surgery causing chronic malabsorption within the past 2 years.\n8. Use within 3 months prior to screening of any of the following:\n\n   i. GLP-1 receptor agonists, GLP-1R\u002FGCGR agonists, GIPR\u002FGLP-1R agonists, or GIPR\u002FGLP-1R\u002FGCGR agonists; ii. Medications affecting body weight, including systemic corticosteroids (intravenous, oral, or intra-articular), tricyclic antidepressants, psychiatric medications, or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproate derivatives, lithium); iii. Chinese herbal medicines, dietary supplements, or meal replacements that affect body weight; iv. Previous or current use of anti-obesity drugs such as sibutramine, orlistat, phentermine, phenylpropanolamine, mazindol, diethylpropion, lorcaserin, phentermine\u002Ftopiramate, naltrexone\u002Fbupropion; consumption of any alcoholic product within 48 hours prior to screening, or a positive alcohol screening test.\n9. Drug abuse or alcohol dependence; severe psychiatric or neurological disorders.\n10. Pregnant or breastfeeding women, or women planning to become pregnant within 1 year.\n11. Special dietary requirements, or allergy to soy, dairy, or other foods.\n12. Current participation in another clinical trial; unwillingness to comply with the lifestyle management and follow-up of this study; or judged by the investigator to be unsuitable for participation.\n13. Unwilling or unable to provide informed consent.",true,"ALL","35 Years","70 Years",{"count":41,"type":42},100,"ESTIMATED","INTERVENTIONAL",[45],"NA","This study is a real-world, prospective clinical cohort study. It will enroll Chinese patients with type 2 diabetes. The aim is to assess the changes in aging biomarkers, primarily DunedinPACE, from baseline to post-remission, and to compare these biomarkers between patients who achieve successful remission and those who do not.",[48],"Type 2 Diabetes",[50,51,52,53,54],"Type 2 diabetes remission","non-surgical intervention","lifestyle modification","epigenetic aging","DunedinPACE","NOT_YET_RECRUITING","2026-07-26",{"date":58,"type":59},"2026-07-30","ACTUAL",{"date":61,"type":42},"2026-07-09",{"date":63,"type":42},"2027-06-30",{"name":5,"class":6}]